Skip to main content

umbralisib

Generic: UMBRALISIB TOSYLATE·Brand: UKONIQ

umbralisib: 4 clinical trials tracked.

umbralisib evidence translation

What we can confirm

4 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about umbralisib, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

Chronic Lymphocytic Leukemia

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (4)

A Phase II Study of BTK Inhibitor Acalabrutinib and PI3Kδ Inhibitor Umbralisib in Combination With Ublituximab (AU2) in Patients With Previously Untreated Mantle Cell Lymphoma (MCL)

NCT04783415Registry updated 2026-07-17·Phase 2
Active, not recruiting

Primary endpoint: Complete Response (CR) Rate After Induction (Six Cycles)

Interventionalopen12 enrolledStarted 2021-03Completion 2026-071 site · United StatesCity of Hope Medical Center

A Phase 2 Study of Acalabrutinib, Umbralisib, and Ublituximab (AU2) in Relapsed and Previously Untreated CLL Patients

NCT04624633Registry updated 2026-02-25·Phase 2

Primary endpoint: Complete Remission (CR) Rate After 24 Cycles

Interventionalopen29 targetStarted 2020-12Completion 2028-011 site · United StatesJennifer R. Brown, MD, PhD

A Phase 2 Study to Assess the Efficacy, Safety, Pharmacokinetic and Pharmacodynamic Parameters of Umbralisib in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)

NCT04163718Registry updated 2026-01-06·Phase 2
Terminated

Primary endpoint: Overall Response Rate (Complete Response and Partial Response)

Interventionalopen12 targetStarted 2019-11Completion 2022-101 site · United StatesH. Lee Moffitt Cancer Center and Research Institute

Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma

NCT03269669Registry updated 2026-02-27·Phase 2
Active, not recruiting

Primary endpoint: Complete response (CR)

InterventionalRandomizedopen73 targetStarted 2018-01Completion 2027-0150 sites · United StatesNational Cancer Institute (NCI)